MYGN Earnings Prediction
The chart below shows how MYGN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, MYGN sees a +1.51% change in stock price 10 days leading up to the earnings, and a +5.18% change 10 days following the report. On the earnings day itself, the stock moves by -0.72%. This data can give you a slight idea of what to expect for the next quarter's release.
MYGN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
213.30M
11.15%
0.85%
Gross Margin
70.23%
0.36%
0.98%
Operating Margin
-8.35%
-37.87%
-29.06%
Net Margin
-10.36%
-67.56%
-40.29%
EPS
-0.24
-68.00%
-41.46%
No Data Available
MYGN Earnings Analysis
Myriad Genetics Inc Corporation (MYGN.O) Earnings Conference Call
Positive
Q3 Revenue Growth Analysis: 11% revenue growth in Q3 compared to last year, reflecting both volume and revenue per test improvements across the portfolio.
Q3 Financial Performance: Generated approximately $150 million in gross profits and $14 million of adjusted EBITDA in Q3, with positive adjusted EPS of $0.06.
GeneSight Revenue Surge: GeneSight revenues increased 34% year-over-year, with a 10% growth in volume and improved revenue per test, driven by strong provider demand and improving payer coverage.
Prenatal Revenue Growth: Women's health team delivered 10% prenatal revenue growth year-over-year and 24% for the trailing 12-month period, indicating strong growth opportunities with new customers.
Strong Liquidity Position: Maintained a strong liquidity position with approximately $149 million in total liquidity, supporting ongoing investments and operational growth.
Negative
Revenue Loss Impact: 1. Loss of Revenue from UnitedHealthcare: The recent policy change by UnitedHealthcare could result in a loss of approximately $40 million in revenue, translating to about $30 million in lost gross profits.
Hereditary Cancer Testing Decline: 2. Decline in Hereditary Cancer Testing Growth: Hereditary Cancer testing revenue grew by only 5%, with the slower growth of the BRACAnalysis CDx business impacting overall performance.
European EndoPredict Sale Impact: 3. Impact of European EndoPredict Sale: The sale of the European EndoPredict business removed about $11 million of annual run rate revenue, despite being accretive to adjusted operating income by over $4 million.
Rising Operating Expenses: 4. Increased Operating Expenses: Operating expenses are expected to be between $565 million to $570 million for the year, indicating a rise in costs despite revenue growth.
Seasonal Testing Volume Decline: 5. Seasonal Softness in Testing Volumes: Typical seasonal softness in July and August affected testing volumes, which could impact future revenue growth projections.
MYGN FAQs
How does MYGN typically perform around its earnings report dates?
Is Myriad Genetics, Inc. (MYGN) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
MYGN Earning Call Sentiment
Myriad Genetics, Inc. (MYGN) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
MYGN.O
2.95%Positive
The earnings call presents a mixed outlook: strong revenue growth in key segments and solid financial performance, but offset by regulatory challenges and competitive pressures. The Q&A reveals uncertainties regarding GeneSight's payer coverage, which could be a risk. The lack of a specific shareholder return plan and operational risks further temper positive sentiment. Given the market cap and these factors, a neutral stock price movement is expected over the next two weeks.